77 related articles for article (PubMed ID: 7489359)
41. p53 gene mutations are not required for early dissemination of cancer cells.
Offner S; Schmaus W; Witter K; Baretton GB; Schlimok G; Passlick B; Riethmüller G; Pantel K
Proc Natl Acad Sci U S A; 1999 Jun; 96(12):6942-6. PubMed ID: 10359818
[TBL] [Abstract][Full Text] [Related]
42. Time-varying prognostic impact of tumour biological factors urokinase (uPA), PAI-1 and steroid hormone receptor status in primary breast cancer.
Schmitt M; Thomssen C; Ulm K; Seiderer A; Harbeck N; Höfler H; Jänicke F; Graeff H
Br J Cancer; 1997; 76(3):306-11. PubMed ID: 9252196
[TBL] [Abstract][Full Text] [Related]
43. [Oncology '96].
Hartmann F; Pfreundschuh M
Med Klin (Munich); 1997 Feb; 92(2):83-100. PubMed ID: 9139216
[No Abstract] [Full Text] [Related]
44. Urokinase plasminogen activator receptor (uPA-R): one potential characteristic of metastatic phenotypes in minimal residual tumor disease.
Allgayer H; Heiss MM; Riesenberg R; Grützner KU; Tarabichi A; Babic R; Schildberg FW
Cancer Res; 1997 Apr; 57(7):1394-9. PubMed ID: 9102229
[TBL] [Abstract][Full Text] [Related]
45. Urokinase-plasminogen-activator receptor expression in disseminated tumour cells in the bone marrow and peripheral blood of patients with clinically localized prostate cancer.
Thomas C; Wiesner C; Melchior SW; Schmidt F; Gillitzer R; Thüroff JW; Pfitzenmaier J
BJU Int; 2009 Jul; 104(1):29-34. PubMed ID: 19154451
[TBL] [Abstract][Full Text] [Related]
46. Minimal residual disease in gastric cancer: evidence of an independent prognostic relevance of urokinase receptor expression by disseminated tumor cells in the bone marrow.
Heiss MM; Simon EH; Beyer BC; Gruetzner KU; Tarabichi A; Babic R; Schildberg FW; Allgayer H
J Clin Oncol; 2002 Apr; 20(8):2005-16. PubMed ID: 11956259
[TBL] [Abstract][Full Text] [Related]
47. Clinical value of extended biologic staging by bone marrow micrometastases and tumor-associated proteases in gastric cancer.
Heiss MM; Allgayer H; Gruetzner KU; Babic R; Jauch KW; Schildberg FW
Ann Surg; 1997 Dec; 226(6):736-44; discussion 744-5. PubMed ID: 9409572
[TBL] [Abstract][Full Text] [Related]
48. Prognostic relevance of urokinase plasminogen activator detection in micrometastatic cells in the bone marrow of patients with primary breast cancer.
Solomayer EF; Diel IJ; Wallwiener D; Bode S; Meyberg G; Sillem M; Gollan C; Kramer MD; Krainick U; Bastert G
Br J Cancer; 1997; 76(6):812-8. PubMed ID: 9310251
[TBL] [Abstract][Full Text] [Related]
49. Individual development and uPA-receptor expression of disseminated tumour cells in bone marrow: a reference to early systemic disease in solid cancer.
Heiss MM; Allgayer H; Gruetzner KU; Funke I; Babic R; Jauch KW; Schildberg FW
Nat Med; 1995 Oct; 1(10):1035-9. PubMed ID: 7489359
[TBL] [Abstract][Full Text] [Related]
50. The urokinase receptor (u-PAR)--a link between tumor cell dormancy and minimal residual disease in bone marrow?
Allgayer H; Aguirre-Ghiso JA
APMIS; 2008; 116(7-8):602-14. PubMed ID: 18834405
[TBL] [Abstract][Full Text] [Related]
51. Relevance of disseminated tumour cells in blood and bone marrow of patients with solid epithelial tumours in perspective.
Vlems FA; Ruers TJ; Punt CJ; Wobbes T; van Muijen GN
Eur J Surg Oncol; 2003 May; 29(4):289-302. PubMed ID: 12711279
[TBL] [Abstract][Full Text] [Related]
52. The biology and analysis of single disseminated tumour cells.
Klein CA
Trends Cell Biol; 2000 Nov; 10(11):489-93. PubMed ID: 11050421
[TBL] [Abstract][Full Text] [Related]
53.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
54.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
55.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
56.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
57.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
58.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
